Gonapeptyl (Triptorelin Acetate)

Gonapeptyl is indicated for several hormone‑dependent conditions where suppression of gonadotropins is required.

• Treatment of advanced prostate cancer in combination with anti‑androgen therapy.
• Management of endometriosis to reduce pelvic pain and lesion growth.
• Reduction of uterine fibroid size and associated bleeding.
• Control of central precocious puberty in children.
• Adjunct in assisted reproductive technology protocols, such as controlled ovarian stimulation for IVF.

The pharmacologic action of triptorelin acetate can produce a range of adverse effects, most of which are related to the induced hypo‑gonadal state.

Common

• Hot flashes, night sweats, and flushing.
• Decreased libido and erectile dysfunction in men.
• Vaginal dryness or menstrual irregularities in women.
• Headache, fatigue, and mild nausea.
• Injection site reactions such as redness or swelling.

Serious

• Severe allergic reaction (anaphylaxis) with rash, swelling, or breathing difficulty.
• Cardiovascular events including hypertension or thromboembolism.
• Bone mineral density loss leading to osteoporosis with long‑term use.
• Liver enzyme elevation indicating possible hepatic injury.
• Pituitary apoplexy (rare) presenting with sudden severe headache and visual changes.

Before initiating Gonapeptyl, clinicians should evaluate patient history and monitor specific parameters to minimize risks.

• Assess cardiovascular status, especially in patients with hypertension or a history of thromboembolic disease.
• Evaluate bone health; consider calcium and vitamin D supplementation for long‑term therapy.
• Review liver function tests prior to treatment and periodically during therapy.
• Use caution in patients with diabetes, as glucose control may be affected.
• Monitor for signs of adrenal insufficiency, particularly after abrupt discontinuation.
• Discuss potential impact on fertility and consider sperm banking or oocyte preservation when appropriate.

Gonapeptyl may interact with other medicines that influence hormone levels, cardiovascular function, or metabolic pathways.

Avoid

• Concomitant use with estrogen‑containing hormone replacement therapy, which can blunt the intended gonadotropin suppression.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce triptorelin plasma concentrations.
• Anticoagulants, as rapid hormonal changes can affect coagulation parameters.

Use with caution

• Anti‑androgen agents used in prostate cancer, requiring dose adjustments and close monitoring.
• Bisphosphonates or denosumab for bone protection, to manage potential bone loss.
• Glucose‑lowering agents, because hormonal shifts may alter blood sugar control.
• NSAIDs, which may increase risk of injection site bleeding.